A Study of the Effects of ALKS 4230 (Nemvaleukin Alfa) on Subjects With Solid Tumors
Part of paid clinical trials in Denver, Colorado.
- Sponsor
- Mural Oncology, Inc
- Study ID
- NCT02799095
- Phase
- PHASE1/PHASE2
- Status
- Completed
Conditions
- Advanced Solid Tumors
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- ALKS 4230 — DRUGIntravenous (IV) infusion over 30 minutes given daily for 5 consecutive days followed by an off-treatment period
- ALKS 4230 + pembrolizumab — DRUGIV infusion of ALKS 4230 over 30 minutes given daily for 5 consecutive days followed by an off-treatment period; pembrolizumab administered IV once with ALKS 4230 on the first day of each cycle
Study Details
To better understand the safety and tolerability of ALKS 4230 in humans
Key Dates
- Start date
- Sep 14, 2016
- Status verified
- May 2025
- Primary completion
- Mar 27, 2023
- Completion
- Aug 2, 2023
Study Design
- Enrollment
- 243 participants (actual)
- Allocation
- NON_RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: ALKS 4230
- Experimental: ALKS 4230 + pembrolizumab
Primary Outcome Measure
Part A: Number of Participants With Dose-limiting Toxicities (DLTs) Based on Common Terminology Criteria for Adverse Events (CTCAE) [ Time Frame: Cycle 1 Day 1 through Cycle 2 Day 15 (Cycle 1 length = 14 days; Cycle 2 length= 21 days) ]
Locations (12)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Mural Oncology Investigational Site | Denver | Colorado | 80045 | - |
| Mural Oncology Investigational Site | Port Saint Lucie | Florida | 34952 | - |
| Mural Oncology Investigational Site | Tampa | Florida | 33610 | - |
| Mural Oncology Investigational Site | Lexington | Kentucky | 40536 | - |
| Mural Oncology Investigational Site | Boston | Massachusetts | 02215 | - |
| Mural Oncology Investigational Site | Detroit | Michigan | 47201 | - |
| Mural Oncology Investigational Site | Buffalo | New York | 14203 | - |
| Mural Oncology Investigational Site | New York | New York | 10016 | - |
| Mural Oncology Investigational Site | Cleveland | Ohio | 44106 | - |
| Mural Oncology Investigational Site | Dallas | Texas | 75230 | - |
| Mural Oncology Investigational Site | Fairfax | Virginia | 22031 | - |
| Mural Oncology Investigational Site | Spokane | Washington | 99208 | - |
Related coverage on Hipa.ai
- Pembrolizumab Combination with Nemvaleukin Alfa Shows Dose-Dependent DLTs in…Pembrolizumab · May 21, 2025 · ClinicalTrials.gov
Find similar trials in Denver, CO
By research site
Related Studies
- TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage CancerPHASE2 · Recruiting · American Society of Clinical Oncology · Birmingham, Alabama
- A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced CancersPHASE1/PHASE2 · Recruiting · Regeneron Pharmaceuticals · Los Angeles, California
- A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)PHASE1 · Recruiting · Merck Sharp & Dohme LLC · Tampa, Florida
- A TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF SHR-A1904 IN SUBJECTS WITH ADVANCED SOLID TUMORSPHASE1/PHASE2 · Recruiting · Jiangsu HengRui Medicine Co., Ltd. · Miami Beach, Florida